Monthly Archives: August 2009
Abbott to collaborate with Pfizer on companion diagnostic test
Abbott has announced that it has entered into an agreement with Pfizer to develop a molecular diagnostic test intended to screen non-small cell lung cancer tumors for the presence of gene rearrangements. Pfizer has developed an investigational agent that selectively … Continue reading
Filed under alliances
BTG sels HySolv to Novartis for up to $10 million
BTG has announced the sale of its HySolv drug delivery technology to Novartis Pharma AG for an initial payment of $0.75 million and potential additional future milestone payments of up to $9.25 million. Under the terms of the agreement, Novartis … Continue reading
Filed under acquisitions
Silence Therapeutics signs siRNA delivery collaboration with Dainippon Sumitomo Pharma
Silence Therapeutics has announced that it has entered into a delivery collaboration with Dainippon Sumitomo Pharma Co., Ltd. of Japan to demonstrate the functional delivery of Silence’s proprietary siRNA molecules to specific targets. Financial details have not been disclosed.
Filed under alliances
Endocyte earns milestone from BMS
Endocyte has announced that it has received a milestone payment from Bristol-Myers Squibb. The payment was triggered by the commencement of a Phase II clinical trial for an epothilone-folate anti-cancer agent identified through the collaboration. Bristol-Myers Squibb and Endocyte entered … Continue reading
Filed under alliances
Phylogica close to announcing partnership
Phylogica has announced that it has been negotiating research partnerships with a number of large pharmaceutical and biotechnology companies and that some of those negotiations have now moved to a very advanced stage. Phylogica was founded and incorporated in 2001 … Continue reading
Filed under alliances
ProStrakan partners with Endo for Fortigel in the USA
ProStrakan Group has announced that it has signed an exclusive licensing and distribution agreement for Fortigel 2% Gel in the USA with Endo Pharmaceuticals. Endo plans to market this product in the US under the brand name FORTESTATM. Under the … Continue reading
Filed under alliances
Are European drug makers more innovative than US companies?
The WSJ is reporting new research, or rather a new analysis of old data, casting doubt on the belief that American pharmaceutical companies are more productive than European companies. The research was funded by the TI Pharma project, a collaboration … Continue reading
Filed under public private partnerships
Fast Forward and Amplimmune ink MS alliance
Amplimmune and Fast Forward, LLC, the National Multiple Sclerosis Society’s subsidiary designed to bridging the gap between research and drug development, have announced a collaboration to support the development of Amplimmune’s AMP-110 therapeutic candidate. The agreement with Amplimmune is the … Continue reading
Filed under public private partnerships
Profectus BioSciences signs collaboration with the PATH Malaria
Profectus BioSciences, a biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, has announced that it has entered into a research collaboration agreement with the PATH Malaria Vaccine Initiative to conduct proof-of-concept studies with its … Continue reading
Filed under public private partnerships
Ligand to acquire Neurogen
Ligand Pharmaceuticals and Neurogen Corporation have announced they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted … Continue reading
Filed under acquisitions
